Status:
COMPLETED
Pneumococcal Vaccine in Untreated CLL Patients
Lead Sponsor:
Karolinska University Hospital
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18-90 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine whether patients with chronic lymphocytic leukaemia (CLL) will benefit from vaccination with a 13-valent conjugated pneumococcal vaccine, Prevenar13, compared ...
Eligibility Criteria
Inclusion
- Untreated CLL patients all Rai stages (0 to IV), as early as possible after diagnosis, always before any therapy with monoclonal antibodies and/or chemotherapy
Exclusion
- Immunosuppressive therapy planned to start within 1 month
- Other malignancies
- Corticosteroids or other immunosuppressive drugs
- Previous allergic reaction to any vaccination in the past
- Neutropenia (PMNs \< 500 cells/mm3)
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT01892618
Start Date
August 1 2013
End Date
December 1 2015
Last Update
January 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Stockholm County, Sweden, 14186